Evidence map›Paper›PMID 31591425›Full record

ArticleScientific reports2019

Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism.

Karl E Johansson, Anne-Lie Ståhl, Ida Arvidsson, Sebastian Loos, Ashmita Tontanahal, Johan Rebetz, Milan Chromek, Ann-Charlotte Kristoffersson, Ludger Johannes, Diana Karpman

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Cellular signaling pathway of Shiga toxin-induced ATP release.Frontiers in cellular and infection microbiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Karl E JohanssonDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Anne-Lie StåhlDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Ida ArvidssonDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Sebastian LoosDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Ashmita TontanahalDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Johan RebetzDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-1673-0684
Milan ChromekDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Ann-Charlotte KristofferssonDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Ludger JohannesInstitut Curie, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology unit, Paris, France.
Diana KarpmanDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden. diana.karpman@med.lu.se.ORCID http://orcid.org/0000-0001-7220-7658
Lund University · SECentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shiga toxin (Stx) is the main virulence factor of enterohemorrhagic Escherichia coli (EHEC), that cause gastrointestinal infection leading to hemolytic uremic syndrome. The aim of this study was to investigate if Stx signals via ATP and if blockade of purinergic receptors could be protective. Stx induced ATP release from HeLa cells and in a mouse model. Toxin induced rapid calcium influx into HeLa cells, as well as platelets, and a P2X1 receptor antagonist, NF449, abolished this effect. Likewise, the P2X antagonist suramin blocked calcium influx in Hela cells. NF449 did not affect toxin intracellular retrograde transport, however, cells pre-treated with NF449 exhibited significantly higher viability after exposure to Stx for 24 hours, compared to untreated cells. NF449 protected HeLa cells from protein synthesis inhibition and from Stx-induced apoptosis, assayed by caspase 3/7 activity. The latter effect was confirmed by P2X1 receptor silencing. Stx induced the release of toxin-positive HeLa cell- and platelet-derived microvesicles, detected by flow cytometry, an effect significantly reduced by NF449 or suramin. Suramin decreased microvesicle levels in mice injected with Stx or inoculated with Stx-producing EHEC. Taken together, we describe a novel mechanism of Stx-mediated cellular injury associated with ATP signaling and inhibited by P2X receptor blockade.

Indexed as

Adenosine TriphosphateAnimalsBenzenesulfonatesBlood PlateletsEnterohemorrhagic Escherichia coliEscherichia coli InfectionsHeLa CellsHemolytic-Uremic SyndromeHumansMicePurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X1Shiga Toxin4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate)Adenosine TriphosphateBenzenesulfonatesPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X1Shiga Toxin

Identifiers

PMID31591425
PMCPMC6779916
OpenAlexW2978610563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.